

10/593217

Applicants : KING, et al.
U.S. Serial No. : Not Yet Known
Filing Date : Herewith
Page : 3

1AP9Rec'd 10/15/93 SEP 2009

IN THE CLAIMS:

Please cancel claims 13 and 22-33 without prejudice to Applicants' right to pursue these matters in a future application.

1. (Original) A method for treating tumor in a subject comprising administering to the subject an effective amount of:
 - (a) VNP40101M, or its equivalent; and
 - (b) a nucleoside, or a nucleoside analog.
2. (Original) A method for inhibiting tumor cell growth comprising contacting the tumor cell with effective amounts of:
 - (a) VNP40101M, or its equivalent; and
 - (b) a nucleoside, or a nucleoside analog.
3. (Currently Amended) The method of claim 1 ~~or~~ 2 wherein the nucleoside is AraC (cytarabine), azacitidine, cladribine, decitabine, gemcitabine, mercaptopurine, thioguanine, fludarabine, clofarabine, troxacitabine or pentostatin.
4. (Currently Amended) The method of claim 1 ~~or~~ 2, wherein the tumor is solid malignant tumor, leukemia or lymphoma.
5. (Currently Amended) The method of claim 1 ~~or~~ 2, wherein VNP40101M and the nucleoside can be administered concurrently or sequentially.

Applicants : KING, et al.
U.S. Serial No. : Not Yet Known
Filing Date : Herewith
Page : 4

6. (Original) The method of claim 1, wherein VNP40101M and the nucleoside are administered intravenously, subcutaneously, or orally.
7. (Original) A method for treating cancer comprising administering to a subject in need thereof an effective amount of VNP4010M and a nucleoside.
8. (Original) The method of claim 7, wherein the cancer is a leukemia and the nucleoside is AraC.
9. (Currently Amended) The method of claim 7, wherein the cancer is a leukemia and the nucleoside is clofarabine or azacitidine.
10. (Currently Amended) The method of claim 8 ~~or 9~~, wherein the leukemia is acute myelogenous leukemia.
11. (Original) The method of claim 8, wherein the dose of VNP40101M is between 100 and 1000 mg/m² and the dose of AraC is between 500 and 5000 mg/m².
12. (Currently Amended) A method for treating or inhibiting tumor in a subject comprising administering to the subject:
 - (a) an effective amount of VNP40101M, or its equivalent; and
 - (b) another anti-tumor therapy.
13. (Canceled)
14. (Currently Amended) The method of claim 12 ~~or 13~~ wherein the other anti-tumor therapy is radiation therapy or administration of another chemotherapeutic agent.

Applicants : KING, et al.
U.S. Serial No. : Not Yet Known
Filing Date : Herewith
Page : 5

15. (Original) The method of claim 14 wherein the chemotherapeutic agent is antimetabolites, etoposide, doxorubicin, taxol, vincristine, cyclophosphamide, mitomycin C, topoisomerase I and topoisomerase II inhibitors (adriamycin, topotecan, camptothecin and irinotecan), cisplatin, carboplatin, tipifarnib (R115777), SCH66336, erlotinib, gefitinib, or gemtuzumab ozogamicin.
16. (Currently Amended) The method of ~~any of claim 1-2, 6-12 and 14-15~~ wherein the subject is a human.
17. (Original) A composition comprising an amount of VNP40101M which produces synergistic effects when used in combination with a nucleoside in treating tumor.
18. (Original) A composition comprising an amount of nucleoside which produces synergistic effects when used in combination with a VNP40101M in treating tumor.
19. (Original) A method of treating tumor growth in a subject comprising administering:
(a) VNP40101M, or its equivalent; and
(b) a nucleoside, or a nucleoside analog,
- wherein the amounts of (a) and (b) administered provide a reduction in tumor growth that is larger than that achieved by administering either (a) or (b) individually.
20. (Original) A method of treating tumor growth in a subject comprising administering components:
(a) VNP40101M; and

Applicants : KING, et al.
U.S. Serial No. : Not Yet Known
Filing Date : Herewith
Page : 6

(b) a nucleoside, or a nucleoside analog,

wherein the amounts of (a) and (b) administered provide a reduction in tumor growth that is larger than that achieved by administering either (a) or (b) individually.

21. (Original) A method of treating tumor growth in a subject comprising administering:

(a) VNP40101M, or its equivalent; and

(b) a nucleoside, or a nucleoside analog is selected from the group consisting of AraC (cytarabine), azacitidine, cladribine, decitabine, gemcitabine, mercaptopurine, thioguanine, fludarabine, clofarabine, troxacitabine and pentostatin.

22-33. (Canceled)